Finance
StaphVAX maker completes common stock offering
Published in Blood Weekly, January 29th, 2004
A total of 9.775 million shares were issued and net proceeds after expenses from this transaction generated approximately $92 million.
Approximately $20 million of proceeds will be used to develop or acquire internal commercial manufacturing capacity for StaphVAX, the company's lead product in development for preventing Staphylococcus aureus blood stream infections, and $9.5 million will be used to repay a term loan under the company's existing credit agreement. Additional planned uses of proceeds include support for future clinical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-01-29)
More Articles from Blood Weekly
- Cancer Therapy
Endurance training can preserve fitness during chemotherapy+SCT - Awards
Wilmot leukemia expert gets national achievement award - Bacterial Contamination
Technology licensed from Infectio for bacterial detection system for platelets - Cancer Therapy
IPSS score has limited prognostic value for MDS patients undergoing intensive treatment - Cancer Therapy
Treatment of post-HDC/HSCT infections reveiwed - Cell Biology
Cells' ability to open blood's floodgates hinges on unexpected factors - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
